Loading clinical trials...

Study of CP-675,206 in Refractory Melanoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of CP-675,206 in Refractory Melanoma

A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma

NCT00254579•AstraZeneca

View on ClinicalTrials.gov

Summary

CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Surgically incurable Stage III or IV melanoma
•One prior systemic treatment for metastatic melanoma
•Measurable disease
•Eastern Cooperative Oncology Group (ECOG) PS = 0 or 1

Exclusion Criteria

•Melanoma of ocular origin
•Received prior vaccine
•Received prior CTLA4-inhibiting agent
•History of, or significant risk for, chronic inflammatory or autoimmune disease
•Potential requirement for systemic corticosteroids

Locations (65)

Research Site

Scottsdale, Arizona, United States

Research Site

Bentonville, Arkansas, United States

Research Site

Fayetteville, Arkansas, United States

Research Site

Little Rock, Arkansas, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Aurora, Colorado, United States

Research Site

Stamford, Connecticut, United States

Research Site

Ocoee, Florida, United States

Research Site

Orlando, Florida, United States

Key Dates

Start Date

December 1, 2005

Primary Completion Date

December 1, 2009

Completion Date

December 1, 2009

Last Updated

June 7, 2012

Enrollment

251

ACTUAL participants

Conditions

Refractory Melanoma

Interventions

CP-675,206

DRUG

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

TERMINATEDPHASE2

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

NCT04093323

HLA-A2 Positive Cells PresentRefractory Melanoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 7, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of CP-675,206 in Refractory Melanoma

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Compassionate Use of Vidutolimod